X4 Pharmaceuticals Plans to Share Q1 2025 Financial Results
X4 Pharmaceuticals is gearing up to unveil its financial results for the first quarter of 2025, following an ambitious journey focused on improving the lives of individuals affected by rare diseases linked to the immune system. The much-anticipated financial report will be released and complemented by vital corporate updates on an upcoming date.
Conference Call and Webcast Details
On the designated day, X4 Pharmaceuticals will host a conference call and a live webcast. This event is scheduled for 8:30 a.m. EDT and will present an opportunity for interested parties to gain insight into the company’s performance and strategic direction. Those wishing to participate in the conference call can do so by dialing 1-800-343-4849 from within the U.S., or for international participants, the number is 1-203-518-9848. To access the call, please enter the conference ID: X4PHARMA.
Accessing the Live Webcast
The live webcast will be conveniently available through the investor relations section of X4 Pharmaceuticals’ website. Following the event, a replay of the discussion will also be accessible for those unable to tune in live, ensuring that stakeholders remain informed and engaged.
Understanding X4 Pharmaceuticals and Its Mission
X4 Pharmaceuticals is dedicated to revolutionizing care for patients grappling with rare and complex immune disorders. At the heart of their mission is the innovative therapy mavorixafor, an orally available CXCR4 antagonist, which has already made strides by reaching the U.S. market under its initial indication name, XOLREMDI®. Furthermore, the company is actively exploring additional applications for mavorixafor and currently leads a pivotal Phase 3 clinical trial named 4WARD, designed to evaluate the efficacy of the treatment for individuals with specific chronic neutropenic disorders.
Recent Developments in Research and Therapy
The company's commitment to investing in research showcases its ambition to address significant unmet medical needs within the realm of immune system disorders. With ongoing studies and trials, X4 is not only positioning itself as a leader in the development of novel therapies but also as a beacon of hope for patients who have limited options.
Connect with X4 Pharmaceuticals
Headquartered in Boston, Massachusetts, X4 Pharmaceuticals stands at the forefront of therapeutic innovation. By fostering community relationships and emphasizing patient feedback, they continue to shape their pipeline effectively. For detailed information on their work, including ongoing trials, patient resources, and corporate updates, stakeholders can visit the company’s official website.
Investor Relations and Media Contacts
For inquiries or further information, investors and media representatives can reach out to Daniel Ferry, Managing Director at LifeSci Advisors, available at (617) 430-7576 or via email. Additionally, Rhiannon Jeselonis from Ten Bridge Communications is also available for press-related inquiries. Their proactive communication efforts ensure that interested parties stay updated on the latest advancements and company news.
Frequently Asked Questions
What will X4 Pharmaceuticals announce on May 1, 2025?
X4 Pharmaceuticals will announce its financial results for the first quarter of 2025 along with corporate updates.
How can I join the X4 Pharmaceuticals conference call?
To join the conference call, you can dial 1-800-343-4849 in the U.S. or 1-203-518-9848 internationally, entering the conference ID: X4PHARMA.
Where can I access the webcast of the call?
The webcast will be accessible through the investor relations section of X4 Pharmaceuticals’ website.
What is mavorixafor?
Mavorixafor is an innovative oral therapy from X4 Pharmaceuticals aimed at treating rare diseases linked to the immune system.
Who can I contact for more information about X4 Pharmaceuticals?
For investor inquiries, you may contact Daniel Ferry at LifeSci Advisors, and for media inquiries, reach out to Rhiannon Jeselonis at Ten Bridge Communications.
